Worldbulletin News

Worldbulletin News Worldbulletin News Portal


06:57, 29 May 2017 Monday
09:20, 15 February 2017 Wednesday

  • Share
Human gene editing approved by US science panel
Human gene editing approved by US science panel

Gene editing should only be used to prevent suffering, international group of scientists asserts

World Bulletin / News Desk

Genetically engineered babies should be allowed in the future when the technology becomes available, according to a report released by a committee comprised of 21 leading scientists.

However, human gene editing must be restricted to only preventing diseases or disabilities in babies, the panel argued. The policy group behind the 261 page report published Tuesday was put together by the National Academy of Sciences and the National Academy of Medicine.

Essentially, the group contends that gene-editing using new technologies could be allowed in human embryos, eggs and sperm, but not to create “designer” children.

“Human genome editing holds tremendous promise for understanding, treating, or preventing many devastating genetic diseases, and for improving treatment of many other illnesses,” Alta Charo, co-chair of the study committee and a bioethicist at University of Wisconsin-Madison, said in a statement.

“However, genome editing to enhance traits or abilities beyond ordinary health raises concerns about whether the benefits can outweigh the risks, and about fairness if available only to some people."

Regulations on studying gene editing need to be especially stringent for changes to “germline” genes, i.e. genes that are inherited from parents to children. Studies of multiple generations would have to be conducted in order to fully understand the implications of editing germline genes.

A global prohibition on human gene editing is not practical, the scientists concede, when access to CRISPR gene editing tools have become so cheap in the past two years. Scientists in China, for example, are already using the technology on human cells.

“Genome editing research is very much an international endeavor, and all nations should ensure that any potential clinical applications reflect societal values and be subject to appropriate oversight and regulation," said committee co-chairs Richard Hynes, of Howard Hughes Medical Institute, and Daniel K. Ludwig, of Massachusetts Institute of Technology, said in a joint statement.

"These overarching principles and the responsibilities that flow from them should be reflected in each nation's scientific community and regulatory processes.”



Legal Notice: Copyright, trade marks and other intellectual property rights in this website can not be reproduced without the prior permission.

  • Share